Vælg sprog

da
  • bg

  • cs

  • da

  • de

  • el

  • en

  • es

  • et

  • fr

  • hr

  • hu

  • it

  • lt

  • lv

  • nl

  • no

  • pl

  • pt

  • ro

  • ru

  • sk

  • sl

  • sv

  • tr

  • uk

Danske
  • Български

  • Čeština

  • Danske

  • Deutsch

  • ελληνική

  • English

  • Español

  • Eesti keel

  • Français

  • Hrvatski

  • Magyar

  • Italiano

  • Lietuvių

  • Latviešu

  • Nederlands

  • Norsk

  • Polski

  • Português

  • Română

  • Русский

  • Slovenský

  • Slovenski

  • Svenska

  • Türkçe

  • Українська

Hvordan foretrækker du at finansierer din konto?

* Vi opkræver ingen kommission for at foretage indbetalinger på din konto

Gilead Sciences

GILD.US $ 67.76 USD

-0.11 $ (-0.16%)

Vækstpotentiale

10.01%

Udbytteindkomst

3.49%

1d
1u
1 måned
6 måneder
Hele tiden

Tilføj til kurv

1 lot = 1 aktie

Købsbeløb:

Mæglerkommission:

Overførselsgebyr:

Anbefaling

Strong Buy

Præstationsbedømmelse

DCF

73.26

ROE

0.01

ROA

-

P/S

3.34

P/B

4.53

Debt / Equity

1.57

Om virksomheden

Gilead Sciences is the largest American biopharmaceutical company engaged in research and development of healthcare products and has a batch production of innovative medicines. The Company was founded in 1987 by a 29-year-old doctor Michael L. Riordan. Gilead's technologies, as well as the drugs themselves, have established themselves as a leading choice when it comes to prevention and cure of the most fatal human diseases. The Company's main efforts have been focused on HIV cure development as well as various treatments of chronic hepatitis B and C, cancers, cardiovascular and respiratory diseases. Among the well-known products are Tamiflu, Atripla, Vistide, Emtriva. The latest successful project of Gilead was Sovaldi, which is an effective medicine for hepatitis C cure. The innovation has become an all-time record of sales. The company's research centers are located in the American cities of Boulder and San Dimas. The company has a rather small staff number, which is about 8,000 employees, with a fairly large turnover of almost $ 25 billion. Today Gilead Sciences boasts of being one of the most speedily developing start-ups in its field. Its headquarters are in California, though the company has its representative offices in other states of North America, as well as in Europe, Asia, and Australia.


Tilmeld dig investeringsideer fra Freedom Finance-analytikere

Vi sender en e-mail en gang om ugen, der kun indeholder de mest relevante og vigtige oplysninger

Tillykke!

Nu vil du altid være opmærksom på, hvilke aktier der er mere rentable at investere i